Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

This program is jointly provided by The University of Tennessee College of Pharmacy, and Catalyst Medical Education, LLC.

This activity is supported by an educational grant from Urovant Sciences, Inc.

ACTIVITY OVERVIEW

This program will review the diagnosis and management of overactive bladder (OAB) and the current pharmacotherapy recommendations, given the availability of newer β₃ AR agonists as additional treatment options. Several case vignettes will be presented to highlight the pharmacist’s role in identifying patients with OAB symptoms, the efficacy and safety and recommended treatment strategies of OAB pharmacotherapy agents, and the particular challenges of managing elderly patients experiencing OAB symptoms in long-term care settings.

INTENDED AUDIENCE

This activity is designed for pharmacists. No prerequisites required.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

• Identify signs and symptoms of undiagnosed, under treated, or inappropriately treated OAB
• Describe the pharmacological challenges of current OAB therapies that contribute to suboptimal outcomes
• Compare the efficacy, safety, and pharmacokinetic profiles of approved and emerging β₃ AR agonists in OAB
• Implement pharmacist-driven strategies to individualize treatment for patients with OAB, considering β₃ AR agonists when appropriate

FACULTY

Mary Bridgeman, PharmD, BCPS, BCGP (Chairperson)
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Internal Medicine Clinical Pharmacist
Robert Wood Johnson University Hospital
New Brunswick, NJ

Dana Saffel, PharmD, CPh, BCGP, FASCP
President and CEO
PharmaCare Strategies
Santa Rosa Beach, FL

DISCLOSURES

Mary Bridgeman, PharmD, BCPS, BCGP, has disclosed the following relevant financial relationships:

• Speaker’s Bureau: AstraZeneca
• Grant Research Support: Merck & Co., Inc.

Dana Saffel, PharmD, CPh, BCGP, FASCP, has disclosed the following relevant financial relationships:

• Consultant: Acadia, Mylan, Neurocrine, Sunovion, Xeris
• Speaker’s Bureau: Acadia, Mylan, Sunovion
• Stock Shareholder (self-managed): Acadia

All of the relevant financial relationships listed for these individuals have been mitigated

Type of Activity: Application-based
Fee Information: This is a complimentary educational activity

Release Date

September 30, 2021

Expiration Date

September 30, 2022

CONTINUING EDUCATION INFORMATION

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.0 contact hours credit (0.10 CEUs). Successfully completing the activity and receiving credit includes: 1) attending the session; 2) completing the educational activity evaluation form and evaluation.

UAN: 0064-9999-21-200-H01-P. It is recommended that you check your NABP CPE Monitor e-profile database 24 hours after the completion of any CE activity to ensure that your credits are posted.

• NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service.
• To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.
• First time participants will be required to setup a profile. All participants should complete an evaluation and submit a claim for CPE credit.